Company profile
Beijing Immunochina Medical Science & Technology Co., Ltd.
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD19Cell therapy | Systemic Lupus Erythematosus | |
IM21 CAR-T cellsNo recent activity | Phase 1 | BCMACell therapy | Multiple Myeloma |
| Phase 1 | CD19 | Systemic Lupus Erythematosus |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.